Analysts at H.C. Wainwright Maintained their Buy rating for Pieris Pharmaceuticals (PIRS) with $12.0 Price Objective; Service International Has 1.23 Sentiment

February 14, 2018 - By Hazel Jackson

Service Corporation International, together with its subsidiaries, provides deathcare services and products in the United States and Canada. The company has market cap of $7.06 billion. The firm operates through Funeral and Cemetery divisions. It has a 19.82 P/E ratio. The Company’s funeral service and cemetery activities comprise funeral service locations, cemeteries, funeral service/cemetery combination locations, crematoria, and related businesses.

Among 7 analysts covering Pieris Pharmaceuticals (NASDAQ:PIRS), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Pieris Pharmaceuticals has $12.0 highest and $7 lowest target. $8.83’s average target is -6.56% below currents $9.45 stock price. Pieris Pharmaceuticals had 16 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 13 by Roth Capital. H.C. Wainwright maintained the shares of PIRS in report on Friday, November 10 with “Buy” rating. The firm has “Market Outperform” rating by JMP Securities given on Wednesday, August 12. The stock has “Buy” rating by H.C. Wainwright on Friday, August 11. The company was initiated on Wednesday, July 22 by Roth Capital. As per Wednesday, December 20, the company rating was maintained by H.C. Wainwright. On Wednesday, October 18 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, February 13. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. On Friday, August 5 the stock rating was reinitiated by Roth Capital with “Buy”.

The stock increased 6.42% or $0.57 during the last trading session, reaching $9.45. About 1.58M shares traded or 155.12% up from the average. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has risen 128.81% since February 14, 2017 and is uptrending. It has outperformed by 112.11% the S&P500.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin drugs. The company has market cap of $423.31 million. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. It currently has negative earnings. The firm primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases.

Analysts await Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to report earnings on March, 28. They expect $-0.14 EPS, up 12.50% or $0.02 from last year’s $-0.16 per share. After $-0.16 actual EPS reported by Pieris Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

The stock decreased 0.13% or $0.05 during the last trading session, reaching $37.65. About 1.58M shares traded or 40.39% up from the average. Service Corporation International (SCI) has risen 20.29% since February 14, 2017 and is uptrending. It has outperformed by 3.59% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 7 insider sales for $24.32 million activity.

Turtle Creek Asset Management Inc. holds 4.69% of its portfolio in Service Corporation International for 1.37 million shares. Salient Trust Co Lta owns 1.13 million shares or 4.68% of their US portfolio. Moreover, First Wilshire Securities Management Inc has 3.36% invested in the company for 343,551 shares. The United Kingdom-based Sarasin & Partners Llp has invested 2.5% in the stock. New South Capital Management Inc, a Tennessee-based fund reported 2.49 million shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>